Providence Saint John's Health Center

Summary

Providence Saint John's Health Center is a medical facility located in Santa Monica, California. This center is recognized for care of Melanoma, Bladder Cancer, Breast Cancer, Cancer, Parkinson's disease and other specialties. Providence Saint John's Health Center is involved with conducting 38 clinical trials across 100 conditions. There are 8 research doctors associated with this hospital, such as Santosh Kesari, MD, Naveed Wagle, MD, Parvin Peddi, MD, and Orrin Troum, MD.

Top PIs

Clinical Trials running at Providence Saint John's Health Center

Cancer

Solid Tumors

Skin Cancer

Liver Cancer

Breast Cancer

Ovarian Cancer

Urothelial Carcinoma

Prostate Cancer

Renal Cell Carcinoma

Bladder Cancer

Pembrolizumab

for Advanced Cancers

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.

Recruiting

2 awards

Phase 3

4 criteria

MDNA11 + Pembrolizumab

for Cancer

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Recruiting

1 award

Phase 1 & 2

AdAPT-001

for Cancer

AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.

Recruiting

1 award

Phase 2

17 criteria